bexagliflozin and SLC5A2

Bexagliflozin (BRENZAVVY®) is an oral medication used to improve glycemic control in adults with type 2 diabetes. It belongs to the class of SGLT2 inhibitors, which lower blood glucose by blocking glucose reabsorption in the kidney and increasing urinary glucose excretion. Benefits include modest weight reduction and mild lowering of blood pressure, while common risks include genital mycotic infections, urinary tract infections, increased urination, and volume depletion.

The drug’s target, SGLT2, is encoded by the SLC5A2 gene, located on chromosome 16. This gene produces a sodium-glucose transporter expressed primarily in the proximal renal tubule, where it is responsible for reabsorbing most of the filtered glucose from the urine back into the bloodstream. Variants in SLC5A2 can cause familial renal glycosuria, but such variants generally do not affect response to SGLT2 inhibitors.

Bexagliflozin does not interact with genes directly. However, it inhibits the SGLT2 protein encoded by SLC5A2. By binding to and blocking the transporter, the drug prevents glucose reabsorption and increases urinary glucose loss. 

The links below provide access to important articles and information relative to bexagliflozin. The links are to external websites and will be checked regularly for consistency.

Bexagliflozin Prescribing Information

Lexicomp Online [Internet]. Hudson (OH): Wolters Kluwer. Zolbetuximab-clzb; [updated 2025 Oct 9; cited 2025 Nov 15]. Available from: https://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7304140?cesid=3wUU76Jh8qj&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DBexagliflozin%26t%3Dname%26acs%3Dfalse%26acq%3DBexagliflozin.